Complete mesocolic excision for colonic cancer: Society for Translational Medicine expert consensus statement
Clinical Guideline

Complete mesocolic excision for colonic cancer: Society for Translational Medicine expert consensus statement

Minhua Zheng1, Junjun Ma1, Abe Fingerhut2, Michel P. Adamina3, Andrey Atroschenko4, Roberto Bergamaschi5, Mariana Berho6, Luigi Boni7, Sami Ahmed Chadi8,9, William Tzu-Liang Chen10, Conor P. Delaney11, Giovanni Dapri12, Igor E. Khatkov4, Nam-Kyu Kim13, Seon-Hahn Kim14, Alexey Karachun15, Davide Lomanto16, Helen MacRae17, Marco Milone18, Mario Morino19, Feza H. Remzi20, Selman Uranues2, Masahiko Watanabe21, Steven Wexner22

1Department of General Surgery, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Minimal Invasive Surgery Center, Shanghai 200025, China; 2Section for Surgical Research, Department of Surgery, University of Graz, Graz, Austria; 3Kantonsspital Winterthur, Department of Surgery, Winterthur, Switzerland & University of Basel, Basel, Switzerland; 4Department of Surgery, Moscow Scientific Center, Moscow, Russia; 5Division of Colon & Rectal Surgery, State University of New York, Stony Brook, New York, USA; 6Department of Pathology, Cleveland Clinic Florida, Fort Lauderdale, FL, USA; 7Department of Surgery, IRCCS - Ca' Granda - Policlinico Hospital, University of Milan, Italy; 8Minimally Invasive Surgery and Colorectal Oncology, Toronto Western Hospital, University Health Network, Toronto, Canada; 9Department of Surgery, University of Toronto, Toronto, Canada; 10Department of Colorectal Surgery, China Medical University Hospital, Taichung, Taiwan; 11Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; 12Department of Gastrointestinal Surgery, Saint-Pierre University Hospital, Brussels, Belgium; 13Division of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea; 14Department of Surgery, Korea University Hospital, Korea University College of Medicine, Seoul, Korea; 15Petrov Scientific Research Institution of Oncology, Saint Petersburg, Russia; 16National University Health System, Minimally Invasive Center, Yong Loo Lin School of Medicine, National University Hospital, Singapore; 17Department of Surgery, University of Toronto, 451 Mt. Sinai Hospital, Toronto, Canada; 18University of Naples Federico II, Naples, Italy; 19Chirurgia Generale II e Centro di Chirurgia Mini Invasiva, Department of Surgery, University of Turin, Turin, Italy; 20Department of Surgery, NYU Langone Medical Center NYC, New York, USA; 21Department of Colorectal Surgery, Cleveland Clinic Florida, Fort Lauderdale, FL, USA; 22Department of Surgery, Kitasato University School of Medicine, Sagamihara, Japan

Correspondence to: Minhua Zheng, MD. Department of General Surgery, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Minimal Invasive Surgery Center, Shanghai 200025, China. Email: zmhtiger@yeah.net; marsnew1997@163.com.

Abstract: Total mesorectal excision (TME), a revolutionary change and a milestone in the history of surgical treatment for rectal cancer, has been widely recognized as the gold standard and is now a routine procedure. The concept of complete mesocolic excision (CME) was proposed based on the similar philosophy as TME, aimed to achieve better surgical quality and improve the oncological outcomes of colon cancer. In recent years, many surgeons have increasingly adopted the principle and conducted clinical trials to verify the effect of CME; however, whether CME should be used as the standard surgical technique is still controversial. In this article, we reviewed and updated the literature. Experts in this field from nine countries were invited to complete a questionnaire concerning CME, with the aim to illustrate the embryological and anatomical basis and reach a consensus of the current situation and future of CME.

Keywords: Laparoscopy; colonic cancer; complete mesocolic excision (CME); anatomy; embryology; level of evidence, consensus


Received: 04 August 2016; Accepted: 02 August 2018; Published: 31 August 2018.

doi: 10.21037/ales.2018.08.02


Introduction

The concept of total mesorectal excision (TME), proposed by Heald over 20 years ago, marked a revolution in the radical treatment of rectal cancer (1,2). Although essentially based on non-randomized, retrospective or historical comparisons, TME is widely recognized today as the gold standard for radical treatment of middle and low rectal cancer (3). Before this concept was envisioned and popularized, carcinological outcomes for colon cancer resection were long thought to be better than those for rectal cancer (4,5), but with widespread application of TME, the gap between the two narrowed (6), indirectly indicating the TME had a positive effect on outcome. In contrast to rectal cancer, progress in terms of oncological endpoints has been slow and marginal for surgical treatment of colon cancer.

Several authors have underlined the value they gave to radical, complete intra-fascial, excision for gastro-intestinal cancer. As early as 1909, Jamieson and Dobson proposed: “no operation for malignant disease can be considered complete without the removal of lymphatic glands”, and further, “The ideal operation consists in removing a considerable length of gut on each side of the growth, the primary glands, together with the vessels running to them from the gut, and the tissues in which these vessels lie—i.e., the so-called “lymphatic area“ (7), interpreted as “sufficient excision of the bowels, complete resection of the mesocolon en-bloc, and central ligation of the vessels” (8). In 2003, Bokey et al. (9) proposed the term of “‘anatomical dissection of the colon” (ADC), for what they and many others believed was already being performed in radical colonic surgery (10,11). In 2009, Hohenberger et al. proposed the name of complete mesocolic excision (CME) (12), corresponding to the terminology most widely used today, and that we will maintain in this report. Well beyond a simple disparity in terminology, however, the question of whether CME represents a revolutionary approach for radical surgery and can improve oncologic outcome in colorectal cancer still remains to be answered.

CME has been performed via laparotomy for many years, but morbidity has been reported to be high in non-expert centers (13-15). Minimal access colorectal surgery has matured steadily over the last decades (16): hence the natural spin-off was whether CME can be performed safely and adequately using minimal access techniques.

A previous consensus conference on CME was published in 2014 (17). The authors proposed “there are sound oncological hypotheses for a more radical approach [to colonic cancer] than has been common up to now”. As for laparoscopic CME, the consensus was “Laparoscopic resection appears to be equally well suited for resection as open surgery” (17).

In this article we propose to review the embryological and anatomical rational behind CME and update the literature concerning clinical experience [only 5 references (out of 86) in the previously mentioned consensus conference were from 2013 or later] (17), in order to place CME in perspective in 2018.

The questions we intend to address include:

  • Have the embryonic and anatomic bases of CME been sufficiently delineated?
  • Has the CME technique been adequately described? (laparotomy, laparoscopy, robotic-assisted surgery)
  • Is CME feasible and safe (laparotomy, laparoscopy, or robotic-assisted surgery) in all patients and by all?
  • What are the specific oncologic outcomes of CME?
  • How does CME fare compared to D3 resections?
  • Are there specific indications for CME? (Should it be performed in all patients, is it necessary for all stages?)
  • What are the future perspectives for CME?
  • Can CME be considered the gold standard in 2017?

Several key questions were formulated and submitted to the experts and answers compiled. An extensive literature research was performed (WU and AF). MEDLINE, Embase, PubMed, Cochrane, and Scopus libraries were queried, and all papers analyzing CME or D3 resection of colonic cancer written in English and published from 1980 were considered for inclusion. Related articles found in the reference lists of the studies retrieved for full-text review were used to complete the search.

Several revised versions of the first draft of the manuscript were circulated through electronic mail for critical analysis and modification until obtaining the final version that was approved by all authors in February 2018.


Have the embryonic and anatomic bases of CME been sufficiently delineated?

Consensus

Number of answers =15 (14 yes/1 no)

Literature review

Both the colonic mesentery and the mesorectum are derived from the dorsal mesentery. During intra-uterine growth, this mesentery surrounds the entire future colon and attaches it to the posterior abdominal wall. Treves et al. (18) described the dorsal mesentery of the left and right colons as being “fixed” to the retroperitoneal wall and then, by “fusing” with the retroperitoneal membrane, the left and right colonic mesenteries finally “disappeared”. Since the transverse colon and the sigmoid mesocolon continue to exist even in adulthood, Treves et al. believed that the colonic mesentery was “discontinuous” in adults (18). Thus, in most textbooks on embryology and anatomy, the ascending and descending colons have been and continue to be described as “retroperitoneal” organs whereas the transverse colon and the sigmoid colon are considered “intraperitoneal” organs (19).

However, over the years, it became apparent that there was a natural anatomical plane between colon and retroperitoneum enabling the operator to detach the left or right colon and isolate the entire colonic mesentery, so achieving complete resection of relevant blood and lymphatic vessels, lymph nodes, and adipose tissues. Toldt et al. (20) described that the left and right colonic mesenteries persisted through adulthood: these mesenteries separate the retroperitoneal wall via a discrete layer of connective tissue. This proper mesangial layer, the lamina mesenteria propria would later be known as the Toldt’s fascia (21), confirmed later by others (22,23) who argued, compared with Treves, that this idea was closer to the “real world” findings in surgical operations. In 2014, Culligan et al. (24) investigated the colonic mesentery with electron microscopy and confirmed the presence of Toldt’s fascia between the mesothelial cell layer of the posterior aspect of the left and right colonic mesenteries and the retroperitoneum.

After extensive anatomic and histological studies, Culligan et al. (23,24) stated (I) the mesocolon was continuous from ileocecal to the rectosigmoid; (II) a mesenteric confluence is found at the ileocecal and rectosigmoid junction as well as at the hepatic and splenic flexures; (III) each flexure (and ileocecal junction) is composed of a complex of peritoneal and omental attachments to the colon centered on a mesenteric confluence; (IV) the proximal rectum originates at the confluence of the mesorectum and mesosigmoid and is continuous with the mesorectum; and (V) a plane occupied by Toldt’s fascia separates the entire apposed mesocolon from the retroperitoneum. In other terms, the mesocolon and retroperitoneum are separated by two mesothelial layers with a connective tissue layer between them (15), corresponding to the CME plane of dissection (23).

Accordingly, the colonic mesentery described contains the blood and lymphatic vessels and nodes emanating from and going to the corresponding colonic segments (25,26). Thus, combined with more contemporary descriptions (27,28), the embryologic and anatomic bases for clear identification and excision of the entire mesocolon have been laid down.

Recently there has been a move to standardize the terminology, both of the anatomy and of the corresponding colectomies (29-31). For the former, terms such as visceral and parietal fascia, anterior renal fascia, anterior pararenal space, mesocolic plane, intramesocolic plane and muscularis propria plane surgery continue to be used. The anatomic-based nomenclature proposed by Coffey et al. (27) includes (I) operation titles used for resectional colonic surgery (i.e., total right mesocolectomy), (II) avoiding disruption of the mesenteric package by dissection in anatomic planes (i.e., colo- and mesofascial planes) and (III) standard dissection technique to ensure complete and intact mesenterectomy (i.e., CME).

Ignjatovic and Bergamaschi have proposed the term of “extended D3 mesenterectomy” to include the dissection of all D3 lymph nodes (31).

The vascular anatomy of the colon also has its importance as many authors have highlighted the extreme variability of arterial and venous colonic vasculature and how these variations may influence the operative tactic, and lymph node yield, particularly in CME or D3 right colectomy (31-34).


Has the CME technique been adequately described?

Consensus

Number of answers =15

  • Laparotomy (15 yes)
  • Laparoscopy (14 yes/1 no)
  • Robotic-assisted surgery (8 yes/7 no)

Number of answers =13

  • Single port (4 yes/9 no)

Literature review

CME via laparotomy has been described in detail in Australia (9), Germany (12) and the United States (35). Slight modifications have been made including:

  • The timing of duodenal Kocher maneuver (9,36);
  • Removal of sub-pyloric and over the pancreatic head lymph nodes (17);
  • Removal of lymph nodes along the left gastroepiploic arcade (17,36).

The laparoscopic technique was detailed by several authors (37-43). The technique described by Shin et al. (37) is a mix of principles described by Bokey et al. (9), Hohenberger et al. (12) and the recommendations made by the Japanese guidelines (2,44).

Several authors have highlighted the importance of the starting point and order of dissection. Zhu et al. (39) emphasized that three anatomic planes must be found. The first surgical plane is the fascia space between the posterior aspect of the ascending mesocolon and the prerenal fascia, to the right of Toldt’s space plane. The second plane separates the posterior ascending mesocolon and the anterior aspect of the pancreatic head and duodenum fascia. The third surgical plane is formed by the posterior aspect of the right-sided transverse mesocolon and the right-sided dorsal mesogastrium fusion fascia.

Likewise, Spasojevic et al. (45,46) defined the “D3 area”: (I) the cranial border runs 5 mm proximal to the line connecting the origins of the gastrocolic trunk of Henlé (GTH) and the middle colic artery (MCA); (II) the medial border runs along the left-hand side of the superior mesenteric artery (SMA); (III) the caudal border runs 5 mm distal to the line connecting the origin of the ICA and the confluence of ileocolic vein to the SMV; and (IV) the lateral border runs 1 cm parallel to the right-hand side of the SMV.

Most authors perform CME with a lateral to medial approach, Matsuda et al. advised a cranial approach for easier access to the middle colic vessels (40). Benz et al. proposed to commence central mesentery dissection starts posteriorly at the level of the 4th part of the duodenum (41,42).

Central vascular ligation (CVL) is the cornerstone of radical excision principles (12,28,45-51). The goal of CVL is to remove as much lymph nodes and associated vascular structures in a vertical or ascending direction potentially removing lymph node metastases, as well as vascular and neural invasion of the regional drainage area (12,17).

The robotic technique was described for both right and left colectomy (16,52-55). All of these studies have suggested that robotic CME can potentially facilitate the difficulties encountered in laparoscopic CME and intra-corporeal anastomosis, especially for the novice. In the systematic review by Trastulli et al. (55), the authors analyzed 12 studies (total of 4,148 patients) of which 10 indicated their approach to mobilization (mostly medial to lateral), with nearly 50% of intra/extracorporeal and hand-sewn or mechanical anastomoses. They found that robotic surgery was associated with longer operative time and higher costs compared to laparoscopic colectomy, but was feasible. However, as these findings were based on observational studies including operations labeled as “colectomy” and the proportion of CME or D3 colectomies was unknown, it is impossible to extrapolate these conclusions to CME or D3.

Ma et al. (56) gave a detailed description of the single port technique, compared with their standard 5-port technique.


Is CME feasible and safe (via laparoscopy or other minimal access techniques) in all patients and by all?

Consensus

Number of answers =15

  • Feasible via laparotomy (15 yes)
  • Feasible via laparoscopy (15 yes)
  • Feasible via robotic (13 yes/2 no)
  • Feasible via single port (9 yes/5 no/1 no experience)

Number of answers =14

  • Safe (acceptable morbidity/mortality) via laparotomy (14 yes)
  • Safe (acceptable morbidity/mortality) via laparoscopy (14 yes)
  • Safe (acceptable morbidity/mortality) via robotic (10 yes/3 no /1 no experience)
  • Safe (acceptable morbidity/mortality) via single port (5 yes/7 no/1 no experience/1 not sure)
  • Feasible in the obese? (8 yes/2 no/4 difficult)
  • Can be performed by all surgeons? (3 yes/10 no/1 not sure)
  • Should be performed by colorectal surgeons only? (7 yes/6 no: 1 not sure)
  • Should be performed laparoscopic experts? (12 yes/1 no/7 not sure)

Literature review

Bokey et al. (57) reported the outcome of 779 of 905 patients who had a potentially curative resection with the previously described “ADC”: overall, the rates of surgical complications were “low” (the exact percentage was not found) and in particular the anastomotic leakage rate was 1.6% (14/864 restorative procedures).

Is CME feasible via laparoscopy?

Continuous progress in technology [application of high-definition (HD) and three-dimensional (3D) and other camera systems, among others] has led to claims of improved precision in lymph node dissection and vascular skeletonization (36,39).

Several single institution non-comparative small studies have reported that laparoscopic CME or D3 resection was feasible and did not compromise patient safety (37,43,44,58-64).

Regarding the comparative studies, Huang et al. (65) provided clinical data from 102 patients with right colon cancer who underwent CME (53 by laparoscopy; 49 by open). No conversions were necessary. There was no statistically significant difference found operative time or postoperative complications, but laparoscopic CME was associated with less intraoperative blood loss, shorter duration of hospital stay.

Storli et al. (66) comparing the data of 251 patients who had undergone either laparoscopic or open CME, found that incidences of complications were lower in the laparoscopic CME group. West et al. (67) compared the specimens obtained via laparoscopic CME or open CME and found that there was no statistically significant difference between the two groups. More recently, Kim et al. (68) compared the results between 99 patients who underwent open surgery with 116 patients undergoing laparoscopy and found that there were fewer postoperative complications, reduced time to soft diet, and reduced length of hospital stay with laparoscopic CME.

In the only randomized trial today (69,70), including 1,057 patients, conversion to open surgery was necessary in 29 (5.4%) patients.

Chyle leakage has been cited as a possible complication associated with extensive (CME) dissection compared to the standard approach. Bae et al. (71) found that chyle leakage occurred less frequently in the laparoscopic group than in the open group (3.5% vs. 14.1%; P=0.015); they attributed this difference to the use of an ultrasound scalpel or vessel-sealing devices for peri-vascular lymph node dissection and a magnified view provided by laparoscopy.

Is CME feasible via single port?

Some studies have suggested that reduced or single port laparoscopic CME was feasible with the potential advantages of reduced postoperative pain and better cosmesis (56,72), but both were non-comparative observational studies.

Is CME safe?

Morbidity and mortality have been summarized in three systematic reviews (28,38,73) with considerable overlap. Killeen et al. (38) analyzed 21 non-randomized, mainly retrospective, studies including 5,246 patients: operative mortality rate was 3.2% and cumulative morbidity rate was 21.5%. About one third of the operations (33.5%) were right colectomies, more than half (52.5%) were left colectomies, while the remaining were transverse colectomies (4.9%) or unspecified (9.1%). This review included both comparative and non-comparative studies. Two years later, Athanasiou et al. (73) compared the outcomes of eight studies [one randomized trial (69,70) and seven non-randomized trials comparing open vs. laparoscopic CME or D3 resections (66,71,74-78)], all published last 10 years. Of note, only one study (76) was included in both reviews. This second review did not find any statistically significant difference in short-term mortality, anastomotic leakage, ileus or deep/surgical site infection/abscess. There was a trend for longer operative time (P=0.05) and shorter duration of hospital stay (P=0.09) with the laparoscopic approach. Laparoscopic right hemicolectomy had a lower surgical site infection rate (P=0.005) compared with open CME. Siani et al. (28) reviewed a mix of comparative and non-comparative studies, and finally did not come to any groundbreaking conclusions. All three reviews concluded that, based on the current evidence in 2014 and 2016, the laparoscopic technique appeared to be feasible and at least as safe (morbidity not statistically significantly different) as the open technique whether used to perform D3 lymphadenectomy or CME for colonic cancer. The only randomized trial (69), however, observed that thirty day morbidity was statistically significantly lower in the laparoscopic group [76/533 (14.3%) vs. 117/524 (22.3%)] probably explaining why duration of stay was shorter in this group.

One further study (not included in any of the three systematic reviews), a non-randomized study from Korea, Kim et al. (68), comparing elective CME either by open surgery (n=99) or laparoscopy (n=116) found that laparoscopic CME conferred short-term benefits in terms of lower rates of postoperative complications, reduced time to soft diet, and reduced length of hospital stay.

Siani et al. recently reported one of the largest series (600 cases) of laparoscopic right colectomy with (79): mortality was 0.5% while morbidity was 35.5%. Readmission and reoperation rates were 5.1% (31 patients; 81% for Dindo-Clavien grade I and II complications) and 2.5% (10 cases for anastomotic leakage and 5 for intestinal obstruction), respectively.

Chyle leakage has been cited as a possible complication associated with extensive (CME) dissection compared to the standard approach. Bae et al. (71) found that chyle leakage occurred less frequently in the laparoscopic group than in the open group (3.5% vs. 14.1%; P=0.015); they attributed this difference to the use of an ultrasound scalpel or vessel-sealing devices for peri-vascular lymph node dissection and a magnified view provided by laparoscopy.

Is CME safe with robotics?

While laparoscopic colectomy has been compared to robotic colectomy in several studies and summarized in meta-analyses (53,55), there is little if any literature specifically comparing laparoscopic to robotic CME or even D3 colectomy. The reduction of morbidity could not be shown in right colectomy (52); better vision was claimed for left colectomy but there was no real comparison (54). In their systematic review, Trastulli et al. (55) found that robotic surgery was associated with less intraoperative blood loss (MD −16.82, P<0.00001) with a lower incidence of overall postoperative complications (OR 0.74, P=0.02) and wound infections (RD −0.02, P=0.03) compared to laparoscopic colectomy. No statistically significant differences were found in the anastomotic leak, or conversion to open surgery rates. However, once again as these findings were based on observational studies only, and the proportion of CME or D3 colectomies was unknown, it is impossible to extrapolate these conclusions to CME or D3.

Is obesity a problem?

One argument often put forward in the discussion why laparoscopic D3 resection (or by extension laparoscopic CME) is performed more often in the East (vs. the West) has been the BMI (14). Several papers have looked at the influence of obesity on the outcome of colectomy but few have specifically concerned laparoscopic CME (9,80-86). In a systematic review and meta-analysis of 13 observational studies (again without any specific reference to CME) looking at the influence of obesity (defined as BMI ≥30 kg/m2 in the Western population, ≥25 kg/m2 in the Asian population) on laparoscopic colorectal resections (80), the authors concluded that laparoscopic colorectal cancer operations were more technically challenging in the obese as the conversion and postoperative complication rates were higher compared to non-obese patients. Notwithstanding, there were no statistically significant differences found between the two groups as concerned oncologic adequacy.

Of interest, however, when they compared the Asian publications (where the proportion of D3 resections should be high), they also found increased lymph node retrieval in the non-obese compared to the obese. For the authors, this observation may be due to the increased technical difficulty in obese compared to non-obese patients or due to an inherent difference in in vivo lymph nodes between these two groups. To date, the association between obesity and adequacy of lymph node retrieval remains unclear (86).

Zou et al. (87) recommended the lateral to medial (caudal to cranial) approach in the obese with a thick mesentery, stating that the retroperitoneal approach to the vessels was easier from behind.

Functional outcome

In the prospective multicenter trial (‘‘Safe Radical D3 Right Hemicolectomy for Cancer through Preoperative Biphasic Multi-detector Computed Tomography’’) in which all soft tissue surrounding the superior mesenteric vessels from the level of the middle colic artery to that of the ileocolic artery was removed, Thorsen et al. (88) compared bowel function [Diarrhea Assessment Scale (DAS)] and quality of life (Gastrointestinal Quality of Life Index (GIQLI) in two consecutive cohorts (n=49 in each) undergoing right colectomy, one with and the other without D3 extended mesenterectomy. The authors concluded that small bowel denervation after right colectomy with D3 extended mesenterectomy leads to increased bowel frequency but does not impact gastrointestinal quality of life and as DAS scores bowel frequency scores were lower when jejunal arteries were cranial to the D3 dissection area, individual anatomical variants can affect postoperative bowel function differently despite standardized surgery (88).

It is difficult to state whether CME (or D3) can be performed adequately, safely and via laparoscopy in nonspecialized centers. In Denmark, this was the case for three of the four units specialized in colorectal surgery and may explain some of the differences observed in outcome (13). Indeed, many surgeons in the Western sphere have been reluctant to apply D3 dissection in the treatment of colorectal cancer considering the surgical difficulty and due to increased postoperative complications (13-15) including more splenic (3.2% vs. 1.2%; P=0.004) and superior mesenteric vein (1.7 vs. 0.2%; P<0.001) injuries, sepsis with vasopressor requirement (6.6% vs. 3.2%; P=0.001) and postoperative respiratory failure (8.1% vs. 3.4%; P<0.001) (13).


What are the specific oncologic outcomes of CME?

Consensus

Number of answers =15

  • Better lymph node yield (12 yes/1 no/2 not sure)
  • Extended length of resection (9 yes/4 no/2 not sure)
  • Better staging (11 yes/2 no/2 not sure)
  • Lower local recurrence rates (10 yes/3 no/2 not sure)
  • Improved survival (10 yes/3 no/2 not sure)

Literature review

Hohenberger et al. [1,438 colon cancer patients of which 1,329 were followed for a median of 103 (range, 1–335) months] in their historical comparison, found that 5-year recurrence rate decreased from 6.5% [1978–1984] to 3.6% [1995–2002] and 5-year survival increased from 82.1% [1978–1984] to 89.1% [1995–2002] (12).

However, the duration of the Hohenberger study was 24 years (1978–2002 with the observation period ending in 2006), during which the emergence of neo-adjuvant, adjuvant and targeted therapies, evolving operative and anesthesia techniques, peri-operative care may potentially have impacted the results. Moreover, were excluded from analysis those patients who died, those with unknown tumor status, those with associated inflammatory bowel disease or familial adenomatous polyposis coli, R1 resections, patients with synchronous or previous cancers, patients having undergone neoadjuvant therapy or those where histological data were missing (at least 200 patients).

Olofsson et al. (89) identified 2084 patients with right-sided cancer in the Swedish Colorectal and found no statistically significant differences in 3-year overall survival, 3-year disease-free survival and local recurrence rate according to the level of ligation of the ileocolic, middle colic and right colic vessels. Only a limited number of case studies (9,12,79,90) and one comparative study (91) have suggested that CME could significantly lower local recurrence rates and increase survival. Of note, in the retrospective large-scale study in Denmark (91), the 4-year disease-free survival rate (all UICC stages confounded) in the CME group was 85.8% (95% CI: 81.4–90.1), which was significantly longer than that in the conventional resection group (75.9%) (72.2–79.7) (P=0.0010). Multivariate Cox regression analysis indicated that CME was a significant and independent prognostic factor for a higher disease-free survival rate, and this finding also applies to patients with UICC stage II/III colon cancer (91).

In the ADC report by Bokey et al. (57) the local recurrence rate was 2.1% (95% CI: 1.3–3.4), the systemic recurrence rate was 10.2% (95% CI: 8.1–12.7), 5-year overall survival was 76.2% (95% CI: 73.0–79.0) and cancer-specific survival rate was 89.8% (95% CI: 87.3–91.9). R0 status was confirmed in 883/905 patients (97.6%; 95% CI: 96.4–98.5). Of note, the width of the confidence intervals in this study was quite narrow, attesting to the robustness of the results, but it remains a single-center (although expert) non-comparative experience.

In another non-randomized historical comparison, Galizia et al. compared the outcomes of patients who had undergone CME for right colonic cancer (n=45) to a historical group having undergone conventional right hemicolectomy (n=58) (92). At 4-year follow-up, local recurrence never developed in the CME but in 21% of the historical control group, disease-specific survival improved (93.3% vs. 75.9%; P=0.0356), while there was no statistically significant difference found in distant metastasis (13.3% and 13.7%, respectively). There were, however, statistically significantly more early stage cancers in the CME group. Nonetheless, the bias of a historical comparison does not allow any conclusions.

In conclusion, it is not possible today to state with formal evidence that oncological outcomes are better than those for traditional colectomy; more evidence from robust studies is needed to clarify the long-term effectiveness of CME.

Open vs. laparoscopic resections

In the meta-analysis performed by Athanasiou in 2016 (73), no statistically significant difference was found in overall survival, disease-free survival, local recurrence and distant metastases between the two approaches. However, of note, once again, no distinction was made between the CME and D3 resections that were analyzed together.

The long term results of the only randomized trial comparing laparoscopic and open CME (non-inferiority study) were published just recently (70): the authors were unable to show that overall survival (main endpoint) after laparoscopic D3 was not inferior to open D3 with any statistically significant difference. Because overall survival did not differ statistically significantly between the two groups, and was actually better than expected, the authors concluded that laparoscopic surgery with Japanese D3 dissection appeared to be acceptable as a treatment option for patients with stage II or III colon cancer.

Quality of the specimen

Similar to the grading system of completeness of TME excision (5), Quirke, West and collaborators have developed a grading system based on the grading system used in the MRC CR07 trial for rectal cancer (93):

  • Mesocolic plane of resection: “Good” surgery, performed along mesofascial interface; producing intact, inviolate mesocolon with a smooth peritoneal surface;
  • Intramesocolic plane of resection: “Moderate” characterized by irregular breaches in the mesocolon, none reaching the muscularis propria of the colon;
  • Muscularis Propria plane of resection: “Poor” characterized by disruption of the mesocolon, with breaches the visceral muscularis propria.

West et al. (26) assessed 399 specimens obtained from surgeries for colon cancer and found that specimens resulting from dissection along the colonic mesentery plane had a statistically significantly larger area of resected mesentery and distance between the mesenteric margin and proper muscular layer than in the specimens obtained via surgeries that had damaged the colonic mesentery or entered the proper muscular layer (i.e., incomplete colonic mesentery). Based on these findings, West et al. elaborated a tissue morphometry procedure (25) in which the distance from the tumor and the closest bowel wall to the high vascular ties, the length of the large and small bowel, and the area of mesentery resected are quantified using the CellD image analyzer (Olympus, Tokyo, Japan) of high-resolution digital color photographs. West et al. (67) then compared the quality of specimen from laparoscopic CME to open CME in published series by grading the plane of resection (26) and tissue morphometry (25). They found (I) the quality of the specimen was similar between groups, although the lymph node yield was statistically significantly lower in the laparoscopic group (difficult to explain given the similarities in specimen quality); (II) intact (“good”) colonic mesentery or proper muscular layer was statistically significantly associated with longer 5-year survival (67).

However, the relation between the quality of CME and increased survival remains unclear (94).

In addition, quality assessment of the specimen should be unified. The resected colon and mesentery should be measured by an experienced surgeon prior to fixation.

Gouvas et al. also compared specimens with morphometric analysis between laparoscopic and open CME (95); specimen quality was not statistically significantly different although there were concerns about the quality of laparoscopic resection for hepatic flexure and transverse colon tumors (shorter length from the tumor to the vascular tie, fewer lymph nodes harvested and a shorter bowel resection).

Lymph node yield

West et al. (94) observed that, compared with the conventional operation for colon cancer, CME was associated with more lymph nodes being removed and analyzed.

In the ADC study (57), the median lymph node count was 15 (range, 0–113). R0 status was confirmed in 883/905 patients (97.6%; 95% CI: 96.4–98.5). As noted previously, results can be considered as robust because of the narrow width of the confidence intervals.

Anatomically correct D3 resection according to the “D3 space” (45,46) implies posterior vertical compartment removal, technically more challenging when the ileocolic artery crosses the superior mesenteric vein posteriorly. According to these studies, addition of the lateral vertical compartment lymphadenectomy increases the lymph node yield by 5 to 6 nodes.

In their systematic review, Gouvas et al. (96) found that CME produced a longer central pedicle that contained more lymph nodes than conventional surgery for colon cancer, but, as others, concluded that there is limited evidence that CME improves long-term oncological outcomes.

For tumors located in the right colon, the lymph nodes along the ileum, right colon and the root of the middle colon vessels should be completely dissected (97). For tumors located at the hepatic flexure, the lymph node-positive rate at the head of the pancreas and gastric curvature has been reported to be 5% and 4%, respectively (97). Therefore, extended resection should transect the right gastro-epiploic vein to remove lymph node station 6 and divide and remove the gastroepiploic arteries along the greater curvature of stomach, i.e., 10–15 cm away from the resected tumor along the gastro-epiploic arcade (97).

In their systematic review (98), Bertelsen et al. were not able to find any statistically significant relationship between extended lymph node dissection and better oncological outcome.

The non-randomized comparative study by Kim et al. (68) found that pathologic (specimen lengths, resection margin distance, number of lymph nodes, and R0 resection) and oncologic outcomes of the laparoscopic CME group were comparable to open CME.

In the recent series of 600 consecutive patients undergoing laparoscopic right colectomy with CME, Siani et al. (90) found that survival was poor (27.7%) when the apical nodes were positive.

In summary, CME has been found to be associated with high disease-free survival in patients with stage I–III colon adenocarcinoma in several studies (57,90,91), but causality cannot be inferred as truly unbiased comparisons to “conventional” techniques, taking into account all confounding factors, are lacking. Moreover, no inter-observer or intra-observer validation of outcomes was available.

Notwithstanding several papers describing the lymph node anatomy [most being cadaveric (45,46)], and the feasibility of extended lymph node retrieval via laparoscopy or robotic approaches, further controlled studies are needed to show that the increased lymph node removal in CME leads to improved prognosis, less local recurrence and better overall survival (98) in unbiased high-quality research (96).


How does CME fare compared to D3 resections?

Consensus

Number of answers =14

  • Better lymph node yield (4 yes/10 no)
  • Extended length of resection (7 yes/7 no)
  • Better staging (2 yes/12 no)?
  • Lower local recurrence rates (3 yes/11 no)?
  • Improved survival (3 yes/11 no)?

Literature review

Japanese surgeons have advocated central node dissection for many years (99). According to the Japanese guidelines, D3 dissection is based on anatomical lymph node dissection at the root of the tumor-feeding artery, and the longitudinal length of large bowel to be resected is determined according to the location of the tumor in relation to the feeding artery (100). CME requires the same high ligation of corresponding vessels and thorough lymph node dissection, as described in D3 resection (14). Moreover, CME puts the emphasis on preservation of anatomic (embryonic) planes with intact mesenteric fascia to which one adds CVL (12). The D3 Japanese guidelines follow the 5–10 cm rule to determine the extent of associated bowel length whereas the length of bowel resected in CME is determined according to the vascular territory (2). While these two techniques differ in their concept, and essentially in the extent of bowel resection, they have the same purpose (67,69,96).

Paquette et al. performed a literature search to determine the survival benefit of proximal vascular ligation colon cancer and made pertinent differentiations between the two techniques [Japanese Society of Cancer of the Colon and Rectum recommendations (2) and CME combined with CVL] (101) with regard to the extent of lymph node dissection. The D3 dissection includes the lymph nodes along (D2) as well as those at the junction and along the root vessel. This means that D3 dissection for right-sided tumors includes lymph nodes along the anterior aspect of the SMV and SMA (central lymph nodes) and for left-sided tumors includes lymph nodes around the inferior mesenteric artery (IMA) while CME and CVL implies complete dissection of the lympho-adipose tissue around the SMV and SMA for right sided tumors (after Kocher maneuver and takedown of the mesenteric attachments to the duodenum and uncinate process of the pancreas), removal of the gastro-epiploic lymph nodes for tumors of the hepatic flexure, and central ligation of the middle colic and right gastroepiploic vessels (with preservation of the pancreaticoduodenal artery) for transverse colon tumors (12). The precisions regarding lymph node dissection around and behind the origin of the middle colic and ileocolic vessels proposed by Spasojevic (45,46) remains to be added to these lymph node protocols.

West et al. compared the specimens of CME (from Erlangen, Germany) to D3 resections (from Tokyo Medical and Dental University and the Tokyo Metropolitan Komagome Hospital) (94) and found that, although the mesocolic plane resection rates were high in all series, the Japanese D3 specimens were statistically significantly shorter (162 vs. 324 mm, P<0.001), resulting in a statistically significantly smaller amount of mesentery (8.3 vs. 18.0 mm2, P<0.001) and nodal yield (median, 18 vs. 32, P<0.001), while the difference in the distance between the high vascular tie and the bowel wall (100 vs. 99 mm) was not found to be statistically significant (P=0.605).

In fact, as the definitions of D2, D3 and CME differ somewhat in the literature, it is difficult to understand what the real differences are from the technical viewpoint. Some teams do not make any distinction between the two (14,15,69). Lu et al. on the other hand, defined CME as D2 plus removal of the lymphatic and adipose tissue and not only the connective tissues around the SMA but include removal of the whole anterior and posterior aspects of the mesocolon and the lymphoadipose tissues covering the anterior surface of the pancreatic head and neck (102). Again, one of the best definitions of the distinction between the two is provided in the review article by Paquette et al. (101).


Are there specific indications for CME?

Consensus

Number of answers =13

  • For all locations (10 yes/3 no)
  • Right-sided (12 yes/1 no)
  • Transverse (including flexures) (12 yes/1 no)
  • Left-sided (not sure 13)

Number of answers =9

  • For all stages? (4 yes/5 no)
  • If no which______________

for metastatic colon cancer, not for early stage, only for clinical stage II & III and IV with curative intent, stage IV should be excluded, only for stage II and III.

Literature review

The 2005 Japanese practice guidelines recommended dissecting Group 3 nodes for cStage II or III colorectal cancer patients (97,99), and since that date, a nation-wide survey of the proportion of patients who underwent D3 LN dissection among Stage II/III patients with CRC found a steady increase in the uptake of the D3 procedure.

In 2012, the Japanese Society for Cancer of the Colon and Rectum (JSCCR) (2) proposed the surgical indications of D3 dissection in its guidelines on the treatment of colorectal cancer as follows (2): D3 lymph node dissection should be performed in patients with lymph node metastasis recognized before or during the surgery or if pre- or intra-operative evaluation indicates that the tumor infiltration has reached the proper muscular layer or deeper.

In 2010, the Chinese Guidelines on the Diagnosis and Treatment of Colorectal Cancer (issued by the Chinese Ministry of Health) (103) also indicated that D3 lymph node dissection should be performed for T2-4N0-2M0 colon cancer. In contrast, CME can be proposed for all stages, T1-4, Nx, M0.

Although it has never been shown formally, some Asian authors claim that D3 colectomy provides better survival in patients with T3 and T4 colonic cancer (104). Whether this can be extended to CME remains to be shown. For Storli et al. (105), survival was improved even for node negative disease (TNM stages 1 and 2): 3 year overall survival and disease free survival was statistically superior in patients undergoing CME vs. “mid-mesenteric” or D2 colectomy (88.1% vs. 79%, and 82.1% vs. 74.3%, respectively). Of note, however, in-hospital postoperative mortality was high (8.6% vs. 2.8%) in the D2 colectomy group, perhaps biasing long-term survival, there was an obvious selection bias in patients undergoing CME, the study was retrospective and lymph node retrieval for D2 colectomy may have differed between the two hospitals. Moreover, there were no statistically significant differences in local or overall recurrence between the groups.

According to West et al. (25), CME could be expected to be most important and extend long-term survival in patients with positive lymph node findings for stage III colon cancer.

Søndenaa et al., in their 2014 consensus statement (17), proposed that while “there are sound oncological hypotheses for a more radical approach [to colonic cancer] than has been common up to now”, “however, this may not necessarily apply in early stages of the tumour stage.”

Several authors have found that up to 5–11% of colon cancer patients have central lymph node metastasis, among which 0.8% may be skip metastasis (106,107). In terms of lymph node characteristics, micrometastases (<2 mm) and free clusters (<0.2 mm) of tumor cells can exist within the colonic mesentery lymph nodes (108). Furthermore, 1–5 micrometastases may be found in a single tumor specimen. This may explain why some authors have found increased survival in N0 patients undergoing extended lymph node resection (109,110). In their recent non-comparative series of 600 consecutive patients, Siani et al. (90) found that while overall survival was 83%, survival in stage II, IIIA/B and in stage IIIC with negative apical nodes was 88.7%, 72.4%, and 71.4%, respectively. Conversely, survival was 27.7% in stage IIIC patients when the apical nodes were positive, suggesting once again that CME may not be the entire answer.


What are the future perspectives for CME?

Literature review

In view of the morbidity associated with extended mesenteric resection, and the absence of formal proof of carcinological improvement, further trials are necessary to define if there is a specific population that might best benefit from extended resections.

Several other studies are underway. The objectives of the T-REX study (International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for colon cancer) (111) are to clarify the actual status of metastatic LN distribution in colon cancer and also provide reliable evidence regarding the optimal length of bowel resection and the extent of central LN dissection (secondary endpoints). Currently underway (1,410 patients recruited up to November 2016) the goal is to include 4,000 patients between May 30, 2013 and Dec 31, 2017. Results are awaited in 2018.

The RELARC randomized trial (102) aims to investigate whether laparoscopic colectomy with extended lymphadenectomy (CME) could improve the oncological outcomes of patients with right-sided colon cancers, compared with D2 lymphadenectomy. This superiority, prospective, multicenter, randomized, two-arm, parallel-group, single-blind clinical trial is expected to last 7 years, including 4 years for recruiting patients and 3 years for follow-up.

Other unanswered questions include: should 3D vascular mapping be mandatory before extended D3 resection (32, 34,112)? The extreme anatomic vascular variability and the danger that can arise when the GCT of Henlé is injured might well justify the precaution (32,46). Additionally, if one admits that one of the key points of CME is to try to eliminate all lymph node deposits, then there may be a role for Indocyanine Green enhanced fluorescence to identify metastatic lymph nodes during operation. Ozben et al. (113) and Nishigori et al. (114) have described the technique of lymph node dissection under the control of real-time visualization of the lymph nodes and lymphatic circulation to ensure complete metastatic lymph node clearance during CME. This can be performed with the robotic system as well as with conventional laparoscopy. Indocyanine green angiography may have an increasing role in colorectal surgery, not only to map the vascular territories and their distribution but also to ensure the adequate vascularity of the distal, and sometimes also, the proximal segments to be anastomosed (115,116). Johnson et al. described their experience in 2016 (117) concluding that fluorescence angiography may provide helpful information when the status of one of the major colonic vessels is unknown or impaired.


Can CME be considered the gold standard in 2017?

Consensus

Number of answers =14 (10 yes/4 no)

Literature review

CME can be performed either via laparotomy, laparoscopically or with single port or robotically-assisted techniques. Technical advances (high-magnification and resolution-based images) have underscored the possibility and the importance of adhering to fundamental surgical planes in order to perform a safe and effective surgery. Surgical specimens can meet the pathological requirements for radical treatment. Although further studies are warranted to identify the potential advantages (e.g., long-term efficacy) of CME for colorectal cancer, it, even as a concept, has the potential to promote the improvement and standardization of surgical techniques (47). As was the case a few decades ago, the concept and the practice of TME was adapted widely without formal proof that it improved cancer outcomes. Even if no one today would challenge the concept, the technique, or the outcomes published, the results observed may not be anything more than a pseudo “Hawthorne” effect (we do things with more application because we have been told that it works). If improved overall survival for CME can be shown across the board, in the same way as happened for TME, it may indeed be the beginning of a new era in the radical treatment of colonic cancer.

In accordance with Willaert and Celen (118) there is no high quality evidence to advocate routine implementation of CME. The reasons are (I) local recurrence may result from systemic disease, more often than from incompletely removed lymph nodes; (II) there is no proof that higher nodal counts improve outcome; (III) metastasis to locoregional nodes probably occurs early and is stochastic rather than stepwise.

However, in harmony with the tenors of open CME (9,12), and as stated by Kim et al. (68), because of fewer postoperative complications, reduced time to soft diet, and reduced length of hospital stay, laparoscopic CME could be considered as a routine elective approach for right-sided colon cancer, if indeed, improved survival and/or less local recurrence can be demonstrated.


Acknowledgements

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479-82. [Crossref] [PubMed]
  2. Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer Int J Clin Oncol 2015;20:207-39. [Crossref] [PubMed]
  3. Lange MM, Rutten HJ, van de Velde CJ. One hundred years of curative surgery for rectal cancer: 1908–2008. Eur J Surg Oncol 2009;35:456-63. [Crossref] [PubMed]
  4. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer: the clue to pelvic recurrence? Br J Surg 1982;69:613-6. [Crossref] [PubMed]
  5. Quirke P, Durdey P, Dixon MF, et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of the lateral tumour spread and surgical excision. Lancet 1986;2:996-9. [Crossref] [PubMed]
  6. Maurer CA, Renzulli P, Kull C, et al. The Impact of the Introduction of Total Mesorectal Excision on Local Recurrence Rate and Survival in Rectal Cancer: Long-Term Results. Ann Surg Oncol 2011;18:1899-906. [Crossref] [PubMed]
  7. Jamieson JK, Dobson JF. VII. Lymphatics of the colon: with special reference to the operative treatment of cancer of the colon. Ann Surg 1909;50:1077-90. [Crossref] [PubMed]
  8. Gao Z, Ye Y, Zhang W, et al. An anatomical, histopathological, and molecular biological function study of the fascias posterior to the interperitoneal colon and its associated mesocolon: their relevance to colonic surgery. J Anat 2013;223:123-32. [Crossref] [PubMed]
  9. Bokey EL, Chapuis PH, Dent OF, et al. Surgical technique and survival in patients having a curative resection for colon cancer. Dis Colon Rectum 2003;46:860-6. [Crossref] [PubMed]
  10. Hogan AM, Winter DC. Complete mesocolic excision (CME): A “novel” concept? J Surg Oncol 2009;100:182-3. [Crossref] [PubMed]
  11. Liang JT, Huang KC, Lai HS, et al. Oncologic results of laparoscopic D3 lymphadenectomy for male sigmoid and upper rectal cancer with clinically positive lymph nodes. Ann Surg Oncol 2007;14:1980-90. [Crossref] [PubMed]
  12. Hohenberger W, Weber K, Matzel K, et al. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis 2009;11:354-64. [Crossref] [PubMed]
  13. Bertelsen CA, Neuenschwander AU, Jansen JE, et al. Short-term outcomes after complete mesocolic excision compared with 'conventional' colonic cancer surgery. Br J Surg 2016;103:581-9. [Crossref] [PubMed]
  14. Chow CF, Kim SH. Laparoscopic complete mesocolic excision: West meets East World J Gastroenterol 2014;20:14301-7. [Crossref] [PubMed]
  15. Emmanuel A, Haji A. Complete mesocolic excision and extended (D3) lymphadenectomy for colonic cancer: is it worth that extra effort? A review of the literature. Int J Colorectal Dis 2016;31:797-804. [Crossref] [PubMed]
  16. Fabozzi M, Cirillo P, Corcione F. Surgical approach to right colon cancer: From open technique to robot. State of art World J Gastrointest Surg 2016;8:564-73. [Crossref] [PubMed]
  17. Søndenaa K, Quirke P, Hohenberger W, et al. The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery. Proceedings of a consensus conference. Int J Colorectal Dis 2014;29:419-28. [Crossref] [PubMed]
  18. Treves F. Lectures on the anatomy of the intestinal canal and peritoneum in man. Br Med J 1885;1:580-3. [Crossref] [PubMed]
  19. Jorge JMN, Habr-Gama A. Anatomy and embryology of the colon, rectum and anus. In: Church JM, Garcia-Aguilar J, Roberts PL. editors. The ASCRS Textbook of Colon and Rectal Surgery, 3rd edition. New York: Springer, 2007:1-22.
  20. Toldt C. An Atlas of Human Anatomy for Students and Physicians, Revised edition. New York: Rebman Company, 1919:407-9.
  21. Goligher J. Treatment of carcinoma of the colon. In: Goligher J. editor. Surgery of the Anus, Rectum and Colon, 5th edition. London: Balliere Tindall, 1984:485-589.
  22. Congdon ED, Blumberg R, Henry W. Fasciae of fusion and elements of the fused enteric mesenteries in the human adult. Am J Anat 1942;70:251-79. [Crossref]
  23. Culligan K, Coffey JC, Kiran RP, et al. The mesocolon: a prospective observational study. Colorectal Dis 2012;14:421-8. [Crossref] [PubMed]
  24. Culligan K, Walsh S, Dunne C, et al. The mesocolon: a histological and electron microscopic characterization of the mesenteric attachment of the colon prior to and after surgical mobilization. Ann Surg 2014;260:1048-56. [Crossref] [PubMed]
  25. West NP, Hohenberger W, Weber K, et al. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010;28:272-8. [Crossref] [PubMed]
  26. West NP, Morris EJ, Rotimi O, et al. Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol 2008;9:857-65. [Crossref] [PubMed]
  27. Coffey JC, Dillon M, Sehgal R, et al. Mesenteric-Based Surgery Exploits Gastrointestinal, Peritoneal, Mesenteric and Fascial Continuity from Duodenojejunal Flexure to the Anorectal Junction--A Review. Dig Surg 2015;32:291-300. [Crossref] [PubMed]
  28. Siani LM, Garulli G. The importance of the mesofascial interface in complete mesocolic excision. Surgeon 2017;15:240-9. [Crossref] [PubMed]
  29. Coffey JC, Sehgal R, Culligan K, et al. Terminology and nomenclature in colonic surgery: universal application of a rule-based approach derived from updates on mesenteric anatomy. Tech Coloproctol 2014;18:789-94. [Crossref] [PubMed]
  30. Sehgal R, Coffey JC. Standardization of the nomenclature based on contemporary mesocolic anatomy is paramount prior to performing a complete mesocolic excision. Int J Colorectal Dis 2014;29:543-4. [Crossref] [PubMed]
  31. Ignjatovic D, Bergamaschi R. Defining the extent of mesenterectomy in right colectomy: a controversy Colorectal Dis 2016;18:649. [Crossref] [PubMed]
  32. Ignjatovic D, Stimec B, Finjord T, et al. Venous anatomy of the right colon: three-dimensional topographic mapping of the gastrocolic trunk of Henle. Tech Coloproctol 2004;8:19-21. [Crossref] [PubMed]
  33. Kuzu MA, İsmail E, Çelik S, et al. Variations in the Vascular Anatomy of the Right Colon and Implications for Right-Sided Colon Surgery. Dis Colon Rectum 2017;60:290-8. [PubMed]
  34. Nesgaard JM, Stimec BV, Ignjatovic D. Is Tracing Vessels to the Origin in Right Colectomy Really Impossible? Dis Colon Rectum 2017;60:e607-e608. [Crossref] [PubMed]
  35. Killeen S, Kessler H. Complete mesocolic excision and central vessel ligation for right colon cancers. Tech Coloproctol 2014;18:1129-31. [Crossref] [PubMed]
  36. Dimitriou N, Griniatsos J. Complete mesocolic excision: Techniques and outcomes. World J Gastrointest Oncol 2015;7:383-8. [Crossref] [PubMed]
  37. Shin JW, Amar AH, Kim SH, et al. Complete mesocolic excision with D3 lymph node dissection in laparoscopic colectomy for stages II and III colon cancer: long-term oncologic outcomes in 168 patients. Tech Coloproctol 2014;18:795-803. [Crossref] [PubMed]
  38. Killeen S, Mannion M, Devaney A, et al. Complete mesocolic resection and extended lymphadenectomy for colon cancer: a systematic review Colorectal Disease 2014;16:577-94. [Crossref] [PubMed]
  39. Zhu DJ, Chen XW. Three surgical planes identified in laparoscopic complete mesocolic excision for right-sided colon cancer. World J Surg Oncol 2016;14:7. [Crossref] [PubMed]
  40. Matsuda T, Iwasaki T, Sumi Y, et al. Laparoscopic complete mesocolic excision for right-sided colon cancer using a cranial approach: anatomical and embryological consideration. Int J Colorectal Dis 2017;32:139-41. [Crossref] [PubMed]
  41. Benz S. The uncinate-first approach for laparoscopic complete mesocolic right hemicolectomy--a video vignette. Colorectal Dis 2016;18:109. [Crossref] [PubMed]
  42. Benz S, Tam Y, Tannapfel A, et al. The uncinate process first approach: a novel technique for laparoscopic right hemicolectomy with complete mesocolic excision. Surg Endosc 2016;30:1930-7. [Crossref] [PubMed]
  43. Feng B, Sun J, Ling TJ, et al. Laparoscopic complete mesocolic excision (CME) with medial access for right-hemi colon cancer: feasibility and technical strategies. Surg Endosc 2012;26:3669-75. [Crossref] [PubMed]
  44. Zheng MH, Zhang S, Feng B. Complete mesocolic excision: Lessons from anatomy translating to better oncologic outcome. World J Gastrointest Oncol 2016;8:235-9. [Crossref] [PubMed]
  45. Spasojevic M, Stimec BV, Dyrbekk AP, et al. Lymph Node Distribution in the D3 Area of the Right Mesocolon: Implications for an Anatomically Correct Cancer Resection. A Postmortem Study. Dis Colon Rectum 2013;56:1381-7. [Crossref] [PubMed]
  46. Spasojevic M, Stimec BV, Gronvold LB, et al. Anatomical and surgical consequences of right colectomy for cancer. Dis Colon Rectum 2011;54:1503-9. [Crossref] [PubMed]
  47. Bertelsen CA, Bols B, Ingeholm P, et al. Can the quality of colonic surgery be improved by standardization of surgical technique with complete mesocolic excision? Colorectal Dis 2011;13:1123-9. [Crossref] [PubMed]
  48. Kanemitsu Y, Hirai T, Komori K, et al. Survival benefit of high ligation of the inferior mesenteric artery in sigmoid colon or rectal cancer surgery. Br J Surg 2006;93:609-15. [Crossref] [PubMed]
  49. West NP, Sutton KM, Ingeholm P, et al. Improving the quality of colon cancer surgery through a surgical education programme. Dis Colon Rectum 2010;53:1594-603. [Crossref] [PubMed]
  50. Kobayashi M, Okamoto K, Namikawa T, et al. Laparoscopic lymph node dissection around the inferior mesenteric artery for cancer in the lower sigmoid colon and rectum: is D3 lymph node dissection with preservation of the left colic artery feasible? Surg Endosc 2006;20:563-9. [Crossref] [PubMed]
  51. Feng H, Zhao XY, Zhang Z, et al. Laparoscopic Complete Mesocolic Excision for Stage II/III Left-Sided Colon Cancers: A Prospective Study and Comparison with D3 Lymph Node Dissection. J Laparoendosc Adv Surg Tech A 2016;26:606-13. [Crossref] [PubMed]
  52. Formisano G, Misitano P, Giuliani G, et al. Laparoscopic versus robotic right colectomy: technique and outcomes. Updates Surg 2016;68:63-9. [Crossref] [PubMed]
  53. Lorenzon L, Bini F, Balducci G, et al. Laparoscopic versus robotic-assisted colectomy and rectal resection: a systematic review and meta-analysis. Int J Colorectal Dis 2016;31:161-73. [Crossref] [PubMed]
  54. Aghayeva A, Baca B, Atasoy D, et al. Robotic Complete Mesocolic Excision for Splenic Flexure of Colon Cancer. Dis Colon Rectum 2016;59:1098. [Crossref] [PubMed]
  55. Trastulli S, Cirocchi R, Desiderio J, et al. Robotic versus Laparoscopic Approach in Colonic Resections for Cancer and Benign Diseases: Systematic Review and Meta-Analysis. PLoS One 2015;10. [Crossref] [PubMed]
  56. Ma J, Zhang L, Zang L, et al. Completed mesocolic excision for right colon cancer: comparison between single-port laparoscopy and conventional laparoscopy. Ann Laparosc Endosc Surg 2016;1:43. [Crossref]
  57. Bokey L, Chapuis PH, Chan C, et al. Long-Term Results Following an Anatomically Based Surgical Technique for Resection of Colon Cancer: A Comparison with Results from Complete Mesocolic Excision. Colorectal Dis 2016;18:676-83. [Crossref] [PubMed]
  58. Adamina M, Manwaring ML, Park KJ, et al. Laparoscopic complete mesocolic excision for right colon cancer. Surg Endosc 2012;26:2976-80. [Crossref] [PubMed]
  59. Lee SD, Lim SB. D3 lymphadenectomy using a medial to lateral approach for curable right-sided colon cancer. Int J Colorectal Dis 2009;24:295-300. [Crossref] [PubMed]
  60. Kang IK, Kim SI, Kang SK, et al. Laparoscopic right hemicolectomy with complete mesocolic excision. Int J Surg 2015;23:12-7. [Crossref]
  61. Kobayashi M, Okamoto K, Namikawa T, et al. Laparoscopic D3 lymph node dissection with preservation of the superior rectal artery for the treatment of proximal sigmoid and descending colon cancer. J Laparoendosc Adv Surg Tech A 2007;17:461-6. [Crossref] [PubMed]
  62. Mori S, Baba K, Yanagi M, et al. Laparoscopic complete mesocolic excision with radical lymph node dissection along the surgical trunk for right colon cancer. Surg Endosc 2015;29:34-40. [Crossref] [PubMed]
  63. Uematsu D, Akiyama G, Magishi A. Radical lymphadenectomy for advanced colon cancer via separation of the mesocolon into two layers as in filleting fish. Surg Endosc 2011;25:1659-660. [Crossref] [PubMed]
  64. Xie D, Yu C, Gao C, et al. An Optimal Approach for Laparoscopic D3 Lymphadenectomy Plus Complete Mesocolic Excision (D3+CME) for Right-Sided Colon Cancer. Ann Surg Oncol 2017;24:1312-3. [Crossref] [PubMed]
  65. Huang JL, Wei HB, Fang IF, et al. Comparison of laparoscopic versus open complete mesocolic excision for right colon cancer. Int J Surg 2015;23:12-7. [Crossref] [PubMed]
  66. Storli KE, Sondenaa K, Furnes B, et al. Outcome after Introduction of Complete Mesocolic Excision for Colon Cancer Is Similar for Open and Laparoscopic Surgical Treatments. Dig Surg 2013;30:317-27. [Crossref] [PubMed]
  67. West NP, Kennedy RH, Magro T, et al. Morphometric analysis and lymph node yield in laparoscopic complete mesocolic excision performed by supervised trainees. Br J Surg 2014;101:1460-7. [Crossref] [PubMed]
  68. Kim IY, Kim BR, Choi EH, et al. Short-term and oncologic outcomes of laparoscopic and open complete mesocolic excision and central ligation. Int J Surg 2016;27:151-7. [Crossref] [PubMed]
  69. Yamamoto S, Inomata M, Katayama H, et al. Short term outcomes randomized controlled trial laparoscopic vs. open D3 dissection for stage II/III colon cancer Ann Surg 2014;260:23-30. [Crossref] [PubMed]
  70. Kitano S, Inomata J, Katayama K, et al. Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2017;2:261-8. [Crossref] [PubMed]
  71. Bae SU, Saklani AP, Lim DR, et al. Laparoscopic assisted versus open complete mesocolic excision and central vessel ligation for right sided colon cancer. Ann Surg Oncol 2014;21:2288-94. [Crossref] [PubMed]
  72. Takemasa I, Uemura M, Nishimura J, et al. Feasibility of single-site laparoscopic colectomy with complete mesocolic excision for colon cancer: a prospective case-control comparison. Surg Endosc 2014;28:1110-8. [Crossref] [PubMed]
  73. Athanasiou CD, Markides GA, Kotb A, et al. Open compared with laparoscopic complete mesocolic excision with central lymphadenectomy for colon cancer: a systematic review and meta-analysis. Colorectal Dis 2016;18:O224-35. [Crossref] [PubMed]
  74. Cong J, Chen C, Feng Y, et al. Comparison of short-term outcomes between laparoscopic and open complete mesocolic excision/D3 radical operation for stage II/III right hemicolon carcinoma. Chin J Clin Oncol 2014;41:1591-6.
  75. Guan GX, Liu X, Jiang WZ, et al. Short-term efficacy of laparoscopic-assisted right hemicolectomy with D3 lymph node dissection in colon cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2010;13:917-20. [PubMed]
  76. Han DP, Lu AG, Feng H, et al. Long-term outcome of laparoscopic-assisted right-hemicolectomy with D3 lymphadenectomy versus open surgery for colon carcinoma. Surg Today 2014;44:868-74. [Crossref] [PubMed]
  77. Sun YW, Chi P, Lin HM, et al. Comparison of efficacy between laparoscopic versus open complete mesocolic excision for colon cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2012;15:24-7. [PubMed]
  78. Zhao LY, Chi P, Ding WX, et al. Laparoscopic vs open extended right hemicolectomy for colon cancer. World J Gastroenterol 2014;20:7926-32. [Crossref] [PubMed]
  79. Siani LM, Lucchi A, Berti P, et al. Laparoscopic complete mesocolic excision with central vascular ligation in 600 right total mesocolectomies: Safety, prognostic factors and oncologic outcome. Am J Surg 2017;214:222-7. [Crossref] [PubMed]
  80. Fung A, Trabulsi N, Morris M, et al. Laparoscopic colorectal cancer resections in the obese: a systematic review. Surg Endosc 2017;31:2072-88. [Crossref] [PubMed]
  81. Leroy J, Ananian P, Rubino F, et al. The impact of obesity on technical feasibility and postoperative outcomes of laparoscopic left colectomy. Ann Surg 2005;241:69-76. [PubMed]
  82. Makino T, Shukla PJ, Rubino F, et al. The impact of obesity on perioperative outcomes after laparoscopic colorectal resection. Ann Surg 2012;255:228-36. [Crossref] [PubMed]
  83. Makino T, Trencheva K, Shukla PJ, et al. The influence of obesity on short- and long-term outcomes after laparoscopic surgery for colon cancer: a case-matched study of 152 patients. Surgery 2014;156:661-8. [Crossref] [PubMed]
  84. Miyamoto Y, Ishii T, Tashiro J, et al. Effects of obesity on the outcome of laparoscopic surgery for colorectal cancer. Surg Today 2014;44:1293-9. [Crossref] [PubMed]
  85. Park JW, Lim SW, Choi HS, et al. The impact of obesity on outcomes of laparoscopic surgery for colorectal cancer in Asians. Surg Endosc 2010;24:1679-85. [Crossref] [PubMed]
  86. Linebarger JH, Mathiason MA, Kallies KJ, et al. Does obesity impact lymph node retrieval in colon cancer surgery? Am J Surg 2010;200:478-82. [Crossref] [PubMed]
  87. Zou L, Xiong W, Mo D, et al. Laparoscopic Radical Extended Right Hemicolectomy Using a Caudal-to-Cranial Approach. Ann Surg Oncol 2016;23:2562-3. [Crossref] [PubMed]
  88. Thorsen Y, Stimec B, Andersen SN, et al. Bowel function and quality of life after superior mesenteric nerve plexus transection in right colectomy with D3 extended mesenterectomy. Tech Coloproctol 2016;20:445-53. [Crossref] [PubMed]
  89. Olofsson F, Buchwald P, Elmstahl S, et al. No benefit of extended mesenteric resection with central vascular ligation in right-sided colon cancer Colorectal Dis 2016;18:773-8. [Crossref] [PubMed]
  90. Siani LM, Pulica C. Laparoscopic complete mesocolic excision with central vascular ligation in right colon cancer: Long-term oncologic outcome between mesocolic and non-mesocolic planes of surgery. Scand J Surg 2015;104:219-26. [Crossref] [PubMed]
  91. Bertelsen CA, Neuenschwander AU, Jansen JE, et al. Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study. Lancet Oncol 2015;16:161-8. [Crossref] [PubMed]
  92. Galizia G, Lieto E, De Vita F, et al. Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. Int J Colorectal Dis 2014;29:89-97. [Crossref] [PubMed]
  93. Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial): Multicentre, randomised controlled trial. Lancet 2005;365:1718-26. [Crossref] [PubMed]
  94. West NP, Kobayashi H, Takahashi K, et al. Understanding optimal colonic cancer surgery: comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. J Clin Oncol 2012;30:1763-9. [Crossref] [PubMed]
  95. Gouvas N, Pechlivanides G, Zervaki N, et al. Complete mesocolic excision in colon cancer surgery:a comparison between open and laparoscopic approach. Colorectal Dis 2012;14:1357-64. [Crossref] [PubMed]
  96. Gouvas N, Agalianos C, Papaparaskeva K, et al. Surgery along the embryological planes for colon cancer: a systematic review of complete mesocolic excision. Int J Colorectal Dis 2016;31:1577-94. [Crossref] [PubMed]
  97. Toyota S, Ohta H, Anazawa S. Rationale for extent of lymph node dissection for right colon cancer. Dis Colon Rectum 1995;38:705-11. [Crossref] [PubMed]
  98. Bertelsen CA, Kirkegaard-Klitbo A, Nielsen M, et al. Pattern of Colon Cancer Lymph Node Metastases in Patients Undergoing Central Mesocolic Lymph Node Excision: A Systematic Review. Dis Colon Rectum 2016;59:1209-21. [Crossref] [PubMed]
  99. Ishiguro M, Higashi T, Watanabe T, et al. Changes in Colorectal Cancer Care in Japan before and after Guideline Publication: A Nationwide Survey about D3 Lymph Node Dissection and Adjuvant Chemotherapy. J Am Coll Surg 2014;218:969-977.e1. [Crossref] [PubMed]
  100. Hida J, Okuno K, Yasutomi M, et al. Optimal ligation level of the primary feeding artery and bowel resection margin in colon cancer surgery:the influence of the site of the primary feeding artery. Dis Colon Rectum 2005;48:2232-7. [Crossref] [PubMed]
  101. Paquette IM, Madoff RD, Sigurdson ER, et al. Impact of Proximal Vascular Ligation on Survival of Patients with Colon Cancer. Ann Surg Oncol 2018;25:38-45. [Crossref] [PubMed]
  102. Lu JY, Xu L, Xue HD, et al. The Radical Extent of lymphadenectomy-D2 dissection versus complete mesocolic excision of Laparoscopic Right Colectomy for right-sided colon cancer (RELARC) trial:study protocol for a randomized controlled trial. Trials 2016;17:582. [Crossref] [PubMed]
  103. Wang JP. Chinese standard for the diagnosis and treatment of colorectal cancer (2010). Zhonghua Weichang Waike Zazhi 2011;14:1-4. [PubMed]
  104. Kotake K, Mizuguchi T, Moritani K, et al. Impact of D3 lymph node dissection on survival for patients with T3 and T4 colon cancer. Int J Colorectal Dis 2014;29:847-52. [Crossref] [PubMed]
  105. Storli KE, Søndenaa K, Furnes B, et al. Short term results of complete (D3) vs. standard (D2) mesenteric excision in colon cancer shows improved outcome of complete mesenteric excision in patients with TNM stages I-II. Tech Coloproctol 2014;18:557-64. [Crossref] [PubMed]
  106. Benz SR, Tannapfel A, Tam Y, et al. Complete Mesocolic Excision for Right-Sided Colon Cancer - the Role of Central Lymph Nodes. Zentralbl Chir 2015;140:449-52. [PubMed]
  107. Nagasaki T, Akiyoshi Y. Prognostic Impact of Distribution of Lymph Node Metastases in Stage III Colon Cancer. World J Surg 2015;39:3008-15. [Crossref] [PubMed]
  108. Sloothaak DA, Sahami S, van der Zaag-Loonen HJ, et al. The Prognostic Value of Micrometastases and Isolated Tumour Cells in Histologically Negative Lymph Nodes of Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis. Eur J Surg Oncol 2014;40:263-9. [Crossref] [PubMed]
  109. Faerden AE, Sjo OH, Bukholm IRK, et al. Lymph Node Micrometastases and Isolated Tumor Cells Influence Survival in Stage I and II Colon Cancer. Dis Colon Rectum 2011;54:200-6. [Crossref] [PubMed]
  110. Merrie AE, Phillips LV, Yun K, et al. Skip metastases in colon cancer: Assessment by lymph node mapping using molecular detection. Surgery 2001;129:684-91. [Crossref] [PubMed]
  111. T-REX study. ClinicalTrials.gov identifier: NCT02938481. Available online: https://clinicaltrials.gov/ct2/show/NCT02938481
  112. Nesgaard JM, Stimec BV, Bakka AO, et al. Navigating the mesentery: a comparative pre- and peroperative visualization of the vascular anatomy. Colorectal Dis 2015;17:810-8. [Crossref] [PubMed]
  113. Ozben V, Cengiz TB, Bayraktar O, et al. Identification of Mesenteric Lymph Nodes in Robotic Complete Mesocolic Excision by near-Infrared Fluorescence Imaging. Tech Coloproctol 2016;20:195-6. [Crossref] [PubMed]
  114. Nishigori N, Koyama F, Nakagawa T, et al. Visualization of Lymph/Blood Flow in Laparoscopic Colorectal Cancer Surgery by Icg Fluorescence Imaging (Lap-Igfi). Ann Surg Oncol 2016;23 Suppl 2:S266-74. [Crossref] [PubMed]
  115. Mizrahi I, Wexner SD. Clinical role of fluorescence imaging in colorectal surgery – a review. Expert Rev Med Devices 2017;14:75-82. [Crossref] [PubMed]
  116. Boni L, David G, Dionigi G, et al. Indocyanine green-enhanced fluorescence to assess bowel perfusion during laparoscopic colorectal resection. Surg Endosc 2016;30:2736-42. [Crossref] [PubMed]
  117. Johnson EK, Hardin MO, Walker AS, et al. Fluorescence Angiography in Colorectal Resection. Dis Colon Rectum 2016;59:e1-e4. [Crossref] [PubMed]
  118. Willaert W, Celen W. Extent of surgery in cancer of the colon: is more better? World J Gastroenterol 2015;21:132-8. [Crossref] [PubMed]
doi: 10.21037/ales.2018.08.02
Cite this article as: Zheng M, Ma J, Fingerhut A, Adamina MP, Atroschenko A, Bergamaschi R, Berho M, Boni L, Chadi SA, Chen WT, Delaney CP, Dapri G, Khatkov IE, Kim NK, Kim SH, Karachun A, Lomanto D, MacRae H, Milone M, Morino M, Remzi FH, Uranues S, Watanabe M, Wexner S. Complete mesocolic excision for colonic cancer: Society for Translational Medicine expert consensus statement. Ann Laparosc Endosc Surg 2018;3:68.